1. PROCABIO A European initiative to develop tailored treatment of prostate cancer by biomarkers

2. Objectives PROCABIO (Tailored treatment of prostate cancer by biomarkers)  Integration biomarkers in updated and improved model for indolent prostate cancer  Integration biomarkers in development of guidelines for efficient strategies for active surveillance  Delivery validated biomarker tools that are easily applicable for high throughput use in clinical and screening settings  Establishment overall acceptance of active surveillance as a treatment modality for indolent prostate cancer For more information, contact e.schenk-braat@erasmusmc.nl

3. 11 clinical & academic partners5 commercial partners Erasmus MC (NL)Abacus Diagnostica (FIN) Institute of Cancer Research (UK)Beckman-Coulter (FR) L’Hôpital Saint-Louis (FR)Epigenomics (GE) Lund University (SE)Gen-Probe Incorporated (USA) Milan National Cancer Institute (I)Orion Diagnostica Oy (FIN) RUNMC (NL) University of Helsinki (FIN)2 advisory partners University of Münster (GE)EORTC (BE) University of Sheffield (UK)Europa Uomo (BE) University of Tampere (FIN) University of Turku (FIN) PROCABIO consortium (18 partners) For more information, contact e.schenk-braat@erasmusmc.nl

4. PROCABIO plan for 3 years For more information, contact e.schenk-braat@erasmusmc.nl Active surveillance trial in 8 centers according to PRIAS protocol with 3 years follow-up Central biorepository of blood and urine Validation in blood, urine or tissue of proteomic and genomic biomarkers discriminating indolent and progressive PCa Informing stakeholders on progress and outcome active surveillance study & biomarker implementation Biomarker implementation in treatment policies Guidelines on active surveillance

5. PCa patients involvement (Europa Uomo) Archival Biomaterials (via P-Mark, ERSPC, ProtecT) Prospective Biomaterials (via PRIAS-study) Genomic, proteomic, molecular pathology Biomarkers Marker based guidelines for PCa patients (EORTC, EAU) Finland France Germany Netherlands Sweden UK Clinical Centres implementation targeted treatment Belgium Italy Lithuania Marker industries  Abacus  Beckman Coulter  Epigenomics  Gen-Probe  Orion Academic Research  Malmö  Nijmegen  Munster  Rotterdam  Sheffield  Turku  Helsinki Europe as a scaffold to integrate research for prostate cancer patients

7. PROCABIO contact details PROCABIO coordinatorPROCABIO project manager Prof. dr. Chris BangmaDr. Ellen Schenk-BraatErasmus MCDepartment of Urology Room H1096JNI, room Be362 T. +31-10-7033607T. +31-10-7043674 F. +31-10-7035838F. +31-10-7044661 h.j.vanalphen@erasmusmc.nle.schenk-braat@erasmusmc.nl

8. Erasmus MC Department of Urology PI Prof. dr. Chris Bangma 50 patients

9. University Hospital Malmö Department of Urology PI Prof. dr. Anders Bjartell 25 patients

10. Institute of Cancer Research, London PI Dr. Chris Parker 100 patients

11. Tampere University Hospital Department of Urology PI Prof. dr. Teuvo Tammela 80-100 patients

12. Milan National Cancer Institute PI Prof. dr. Riccardo Valdagni 40 patients

13. EAU Best paper 2007 by a resident

14. Integrating Europe for Prostate Cancer 2007 Prostate Cancer Risk Calculator Patient organisations …early detection… Biomarker research 2002 Health care professionals 2007 Prostate Cancer International study of Active Surveillance 2006 PROCABIO Prostate Cancer Biomarker research in clinical setting of Active Surveillance 2008